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To assess whether PAF could be involved in the
gentamicin-induced nephrotoxicity, we have studied the
effect of PAF antagonist BN-52021 on renal function in
rats after gentamicin (GENTA) treatment. Experiments
were completed in 21 Wistar rats divided into three
groups: group GENTA was injected with gentamicin 100
mg kg
-1 body wt/day s.c. for 6 days. Group GENTA +
BN received gentamicin and BN-52021 i.p. 5 mg kg
-1
body wt/day. A third group served as control. Rats were
placed in meta-bolic cages and plasma creatinine and
creatinine clearance were measured daily. GENTA group
showed a progressive increase in plasma creatinine, a drop
in creatinine clearance and an increase in urinary excretion
of N-acetyl--n-glucosaminidase and alkaline phos-
phatase. GENTA + BN group showed a lesser change in
plasma creatinine and a creatinine clearance, but no
difference with GENTA group in urinary excretion of
NAG and AP were observed. Histological examination
revealed a massive cortical tubular necrosis in rats
treated with gentamicin, whereas in BN-52021 injected
animals tubular damage was markedly attenuated. The
present results suggest a role for PAF in the gentamicin-
induced nephro-toxicity.
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Introduction
Gentamicin is an aminoglycoside frequently used
in the treatment of gram-negative infection. One of
its main side effects is nephrotoxicity, even at the
lower therapeutical doses. Gentamicin is specific-
ally reabsorbed by proximal tubular cells,
2 and
accumulated into the lysosomes, inducing PIP2-
enriched phospholipidosis and thus, causes cellular
necrosis. However, although gentamicin-induced
nephrotoxicity is mainly tubular, and cellular
necrosis confined to cells of the nephron segment
where gentamicin is absorbed, chronic treatment
with gentamicin has been reported to induce
decreases in glomerular filtration rate (GFR).
4
Platelet activating factor (PAF) has been shown
to be produced by the kidney5’6 and to be involved
in the reduction of GFR observed in experimental
models of acute renal failure (ARF). 7’8
To assess whether PAF could be involved in the
gentamicin-induced nephrotoxicity, we have stud-
ied in rats after gentamicin treatment, the effect on
renal function and morphology of inhibiting the
interaction of PAF with its receptor using a specific
antagonist of PAF, BN-52021.
Methods
Experiments were completed in 21 Wistar rats
weighing about 250 g. The animals were placed into
individual metabolic cages for 4 days, and urine,
free of food and faeces, was collected daily into
graduate cylinders under water-equilibrated mineral
oil, 2 days before and 6 days after starting
gentamicin treatment. On the last 2 days, urine was
collected on ice to determine enzymatic urine
activity. A blood sample (150 #1) was taken from
the caudal vein before and daily after starting
gentamicin treatment. Rats were divided into three
experimental groups:
Group I. Control rats received a daily s.c.
injection of 0.5 ml isotonic saline solution and i.p.
injection of 0.5 ml of saline solution, for 6 days.
Group II. This group was injected with
gentamicin-sulphate 100 mg kg
-1 body wt/day s.c.
in 0.5 ml and saline solution 0.5 ml i.p., for 6 days.
Group III. This group received gentamicin in
the same conditions as group II and BN-52021 i.p.
5 mg kg
-1 body wt/day in 0.5 ml saline solution,
for 6 days.
The last day, rats were slightly anaesthetized with
ether, and 5 ml of blood was taken from the
abdominal aorta into heparinized syringes. The
kidneys were removed and small pieces from one
kidney were placed in buffered 10% formalin and
processed for subsequent examination (in a blinded
fashion) by light microscopy. In the second kidney,
the cortex was isolated and gentamicin extracted
from renal cortex by NaOH digestion according to
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the method of Brown et al.
lo and its content was
determined by a fluorescence polarization using the
Cobas Fara II system (Roche).
Morphological changes were analysed in a blind
way by a pathologist (M.A.) and scored with a
semi-quantitative scale evaluating the changes more
frequently found in acute renal failure. Higher
scores represent more severe damage (maximum
score per tubule was ten with points given for
brush-border loss (1 point), cell membrane bleb
formation (1 or 2 points), interstitial oedema (1
point), cell necrosis (1 or 2 points), cytoplasmic
vacuolization (1 point), tubular lumen obstruction
(1 or 2 points) and lympho-monocyte infiltration (1
point).
Plasma and urine creatinine were determined by
a colorimetric method based on the Jaff reaction.
N-acetyl-fl-D-glucosaminidaze (NAG) was mea-
sured by a spectrofluorimetric method
11 and alkaline
phosphatase (AP) by a spectrophotometric method
(Boehringer Mannheim).
12
Gentamicin sulphate was a gift of Antibioticos
Farma, Madrid, Spain; BN-52021 was obtained
from Institut Henri Beaufour, Les Ulis, France. All
the other reagents were purchased from Sigma.
Data are expressed as mean -+- SEM. One or two
ways analysis of variance were used to compare the
effects of drug treatment between groups. Ap value
lower then 0.01 was considered statistically
significant.
Results
In rats that received gentamicin, renal function
deteriorated over 5 days, with a two-fold increase
in plasma creatinine and a drop in creatinine
clearance (Figs 1 and 2). In addition these animals
showed an increase in urinary excretion of
N-acetyl-fl-D-glucosaminidase and alkaline phos-
phatase (Table 1). Rats treated with gentamicin and
BN-52021 showed a lower increase in plasma
creatinine and a lower decrease in creatinine
clearance (Figs 1 and 2). However no differences in
urinary excretion of NAG and AP were observed
between BN-52021 treated and untreated animals.
The renal cortical gentamicin concentration of
rats injected with gentamicin plus BN-52021
(375 2/,g/g) tended to be higher than in those
injected with gentamicin alone (310--b_ 43/,g/g;
p NS). Gentamicin was undetectable in control
rats.
Light microscopy examination (Table 2) revealed
patchy cell necrosis in more than 85% of the
proximal tubules in kidneys of rats injected with
gentamicin. In addition, tubular lumen was
freqently filled with hyaline casts or heterogeneous
cellular debris. In contrast, rats treated with
BN-52021, manifest cell necrosis was observed in
less than 25% of cells, although most proximal cells
showed signs of cell degeneration, as cytoplasmic
vacuolization, membrane blebs and loss of the
brush border. Tubular lumens obstructed with
hyaline material were rare. No glomerular damage
was observed in gentamicin-treated rats receiving
or not BN-52021. Kidneys from the control rats
revealed neither cellular necrosis nor tubular
obstruction.
Discussion
From the data shown above, it can be deduced
that the treatment with gentamicin induces a
reduction in glomerular filtration rate, manifested
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FIG. 1. Time course of plasma creatinine after gentamicin injection in the three groups of rats. Data represents
the mean ___
SEM. All the curves are significantly different to each other (p < 0.01 two ways analysis of
variance).
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FIG. 2. Time course of creatinine clearance after gentamicin injection in the three groups of rats. Data represents the mean SEM.
All the curves are significantly different to each other (p < 0.01 two ways analysis of variance).
Table 1. Urinary excretion of NAG and AP
NAG (U/d) AP (nKat/d)
CONT 70.78 _+ 20.60 0.048 ___
0.02
GENT 673.22 -I- 109.1" 2.955 +_ 1.59"
G + BN 621.06 _+ 80.8* 1.827 _+ 0.90*
Data are means ___
SEM.* p < 0.01 with control group
(one way analysis of the variance). Abbreviations"
CONT" control group" GENT: group treated with
gentamicin (100 mg/kg/day) G + BN" group treated
with gentamicin and BN-52021 (5 mg/kg/day).
NAG" N-Acethyl-fl-D-glucosaminidase" AP" alka-
line phosphatase.
by the progressive reduction of the creatinine
clearance, and the increase in plasma creatinine. In
addition, these animals showed a marked increase
in the urinary excretion of NAG and AP. NAG is
a lysosomal enzyme, and its increased urinary
excretion reflects the lysosomal damage induced by
gentamicin.
3 AP is a brush border-associated
enzyme, and its increased urinary excretion reflects
the cellular necrosis induced by the drug. The
data agree with the effect of gentamicin on renal
function reported in previous studies.2’3
When the rats, in addition to gentamicin, were
treated with BN-52021, a PAF antagonist, the
increase in plasma creatinine was slower than that
shown by gentamicin treated, BN-untreated rats.
According to these results, the decrease in
creatinine clearance was less marked in BN-treated
than in untreated rats. Previous studies from our
laboratory have also demonstrated a protection of
the renal function by PAF antagonists in several
models of acute renal insufficiency.’ Thus, it could
be suggested that gentarnicin treatment induces a
release of PAF by some kind of renal cells, and this
PAF could act on renal resistance vessels and/or
rnesangial cells, where receptors for PAF exist, thus
inducing a decrease in GFR, and renal blood flow.
Table 2. Scores of tubular damage among the different groups
CONT GENTA GENTA + BN
Brush-border loss 0.08 _
0.001 0.80 _+ 0.12*
Blebs 0.08 _
0.001 2 1.08 _+ 0.13*
Interstitial oedema 0.00 -!- 0.00 0.22 +_ 0.12* 0.08 +_ 0.02
Cytoplasmic vacuolization 0.22 _+ 0.05 0.89 +_ 0.013*
Necrosis 0.03 +_ 0.00 1.81 +_ 0.13" 1.04 +_ 0.16*
Tubular obstruction 0.00 _+ 0.00 1.62 _+ 0.14" 0.25 -I- 0.14*
Infiltration 0.00 +_ 0.00 0.40 +_ 0.11 0.10 +_ 0.005*
TOTAL 0.41 _+ 0.05 8.05 _+ 0.40* 4.27 _+ 0.35*
Abbreviations" CONT" control group" G ENTA" group treated with Gentamicin (100
mg/kg/day)" GENTA+BN" group treated with gentamicin and BN-52021 (5
mg/kg/day). As the cells were too damaged, these concepts were impossible to be
scored. A maximum value was given in order to obtain the total score. Data are
mean +_ SEM" *statistically significant differences (p < 0.05, one way analysis of the
variance) with respect to control rats; =lfstatistically significant differences (p < 0.05, one
way analysis of the variance with respect to G ENTA-treated rats.
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Although it cannot be deduced from the present
experiments, PAF is probably originated in the
glomerular endothelial and mesangial cells. In this
regard, we have previously demonstrated that
glomeruli from rats with acute renal failure show
an increased production of PAF. 14
Urinary excretion of NAG and AP, a marker of
tubular damage,
13 was similar in gentamicin-treated
rats, with or without treatment with BN-52021,
thus suggesting that tubular damage was similar in
both groups of rats. However, morphological
studies revealed that the severity of proximal cell
necrosis was greatly attenuated by BN-52021. PAF
does not seem to act directly on tubular cells, since
there are not receptors in these cells.
15 Thus, the
possible mechanism by which BN-52021 attenuated
cell necrosis ameliorates the PAF-mediated genta-
micin-induced renal ischemia that probably super-
imposes the direct tubular action of gentamicin.
Cortical levels of gentamicin were also similar in
both groups of animals. Thus, it can be deduced
that the protective effect of BN-52021 against
gentamicin nephrotoxicity was not mediated by an
inhibition of cortical cell accumulation of gentami-
cin.
In summary, the present results demonstrate that
BN-52021 blunted the fall in GFR and greatly
attenuated the severity of proximal cell necrosis
induced by gentamicin. The data suggest a role
for PAF in the gentamicin-induced nephrotoxicity.
However further experiments, using other structur-
ally-unrelated PAF antagonists, as well as measur-
ing the production of PAF by kidney structures
after treatment with gentamicin are necessary to
confirm a role of PAF in gentamicin-induced
nephrotoxicity.
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